Bacitracin: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 1: Line 1:
{{drugbox
{{drugbox
| IUPAC_name =  
| IUPAC_name = (4''R'')-4-[(2''S'')-2-({2-[(1''S'')-1-amino-2-methylbutyl]- 4,5-dihydro-1,3-thiazol-5-yl}formamido)-4-methylpentanamido]-4-{[(1''S'')- 1-{[(3''S'',6''R'',9''S'',12''R'',15''S'',18''R'',21''S'')- 18-(3-aminopropyl)-12-benzyl-15-(butan-2-yl)-3-(carbamoylmethyl)- 6-(carboxymethyl)-9-(1''H''-imidazol-5-ylmethyl)-2,5,8,11,14,17,20- heptaoxo-1,4,7,10,13,16,19-heptaazacyclopentacosan-21-yl]carbamoyl}- 2-methylbutyl]carbamoyl}butanoic acid
| image =
| image = Bacitracin A.svg
| CAS_number = 1405-87-4
| CAS_number = 1405-87-4
| ATC_prefix = D06
| ATC_prefix = D06

Revision as of 14:06, 30 June 2009

{{drugbox | IUPAC_name = (4R)-4-[(2S)-2-({2-[(1S)-1-amino-2-methylbutyl]- 4,5-dihydro-1,3-thiazol-5-yl}formamido)-4-methylpentanamido]-4-{[(1S)- 1-{[(3S,6R,9S,12R,15S,18R,21S)- 18-(3-aminopropyl)-12-benzyl-15-(butan-2-yl)-3-(carbamoylmethyl)- 6-(carboxymethyl)-9-(1H-imidazol-5-ylmethyl)-2,5,8,11,14,17,20- heptaoxo-1,4,7,10,13,16,19-heptaazacyclopentacosan-21-yl]carbamoyl}- 2-methylbutyl]carbamoyl}butanoic acid | image = Bacitracin A.svg | CAS_number = 1405-87-4 | ATC_prefix = D06 | ATC_suffix = AX05 | ATC_supplemental = R02AB04 (WHO) | PubChem = 439542 | DrugBank = APRD00816 | C = 66 | H = 103 | N = 17 | O = 16 | S = 1 | molecular_weight = 1422.69 g/mol | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | pregnancy_category = | legal_status = OTC/℞-only | routes_of_administration = Topical, intramuscular }}

WikiDoc Resources for Bacitracin

Articles

Most recent articles on Bacitracin

Most cited articles on Bacitracin

Review articles on Bacitracin

Articles on Bacitracin in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Bacitracin

Images of Bacitracin

Photos of Bacitracin

Podcasts & MP3s on Bacitracin

Videos on Bacitracin

Evidence Based Medicine

Cochrane Collaboration on Bacitracin

Bandolier on Bacitracin

TRIP on Bacitracin

Clinical Trials

Ongoing Trials on Bacitracin at Clinical Trials.gov

Trial results on Bacitracin

Clinical Trials on Bacitracin at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Bacitracin

NICE Guidance on Bacitracin

NHS PRODIGY Guidance

FDA on Bacitracin

CDC on Bacitracin

Books

Books on Bacitracin

News

Bacitracin in the news

Be alerted to news on Bacitracin

News trends on Bacitracin

Commentary

Blogs on Bacitracin

Definitions

Definitions of Bacitracin

Patient Resources / Community

Patient resources on Bacitracin

Discussion groups on Bacitracin

Patient Handouts on Bacitracin

Directions to Hospitals Treating Bacitracin

Risk calculators and risk factors for Bacitracin

Healthcare Provider Resources

Symptoms of Bacitracin

Causes & Risk Factors for Bacitracin

Diagnostic studies for Bacitracin

Treatment of Bacitracin

Continuing Medical Education (CME)

CME Programs on Bacitracin

International

Bacitracin en Espanol

Bacitracin en Francais

Business

Bacitracin in the Marketplace

Patents on Bacitracin

Experimental / Informatics

List of terms related to Bacitracin

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Bacitracin is a mixture of related cyclic polypeptides produced by organisms of the licheniformis group of Bacillus subtilis var Tracy. Its unique name derives from the fact that the bacillus producing it was first isolated in 1943 from a knee scrape from a girl named Margaret Tracy.[1] As a toxic and difficult-to-use antibiotic, bacitracin doesn't work well orally. However, it is very effective topically.

Bacitracin is synthesised via the so-called nonribosomal peptide synthetases (NRPSs), which means that ribosomes are not involved in its synthesis.

Mechanism of action

Bacitracin interferes with the dephosphorylation of the C55-isoprenyl pyrophosphate, a molecule which carries the building blocks of the peptidoglycan bacterial cell wall outside of the inner membrane [3].

Clinical use

Bacitracin is used in human medicine and is "approved by the FDA for use in chickens and turkeys."[2]

As bacitracin zinc salt, and in combination with other topical antibiotics (usually polymyxin B and neomycin), it is used in ointment form for topical treatment of a variety of localized skin and eye infections, as well as for the prevention of wound infections. In the United States a popular brand name Neosporin contains Bacitracin as one of its antibiotic agents along with Neomycin and Polymyxin B. Bacitracin can also be bought in pure form for those with allergies.

It is also commonly used as an aftercare antibiotic on tattoos. It is preferred over Neosporin because of its fewer ingredients, which lowers chances of an allergic reaction.[3]

In infants, it is sometimes administered intramuscularly for the treatment of pneumonias. This formulation is sold under the brand name Baciim®.

References

  1. Johnson B, Anker H, Meleney F (1945). "Bacitracin: a new antibiotic produced by a member of the B. subtilis group". Science 102 (2650): 376–377.
  2. Antibiotic use on the farm hurts people—and doesn’t help the bottom line. Discover Magazine. Accessed on September 16, 2007.
  3. http://tattoo.about.com/cs/tatfaq/a/aftrcr_cntrdctn.htm

Template:PolypeptideAntiBiotics Template:Throat preparations Template:SIB

Template:WikiDoc Sources